(Bloomberg) Sosei Group Corp. has lost over half of its market value in just three days on concern about its outlook after Pfizer Inc. said Monday it will discontinue the partnered development of a diabetes and obesity drug.Most Read from BloombergSwitzerland Blocks Sale of Leopard 1 Tanks Bound for UkrainePutin Claims He’s Back in Control. Russia’s Elite Isn’t SureQatar Group Now Confident of Winning Manchester United RaceSweden Police Give Permit to Koran Burning Near Stockholm MosqueUBS Pr
Edesa Biotech Inc (NASDAQ: EDSA) released findings from an in vitro study involving its monoclonal antibody candidate, paridiprubart. The study, conducted by the University of Toronto, ran parallel to Edesa's ongoing clinical study of EB05 (paridiprubart) in hospitalized Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS), a severe form of respiratory failure characterized by extensive inflammatory damage to the lungs. The preprint research results revealed demonstrate that various
Whether you love them or hate them, penny stocks are contentious. These tickers, which trade for less than $5 per share, have earned a reputation on Wall Street for their divisive nature, leaving investors struggling to find common ground on the matter. The appeal is clear. For the same price as one share of a more well-known company, investors can snap up hundreds of shares of a penny stock. What’s more, the fact that even minor share price appreciation can translate to irresistible percentage
The company unveils the creation of the Institute of Human Biology, which will provide efficacy studies of drug candidates using miniature ‘living replicas’ of human tissues and organs.
The company unveils the creation of the Institute of Human Biology, which will provide efficacy studies of drug candidates using miniature ‘living replicas’ of human tissues and organs.